Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

Summary: Efforts to target glutamine metabolism for cancer therapy have focused on the glutaminase isozyme GLS. The importance of the other isozyme, GLS2, in cancer has remained unclear, and it has been described as a tumor suppressor in some contexts. Here, we report that GLS2 is upregulated and es...

Full description

Bibliographic Details
Main Authors: Michael J. Lukey, Ahmad A. Cluntun, William P. Katt, Miao-chong J. Lin, Joseph E. Druso, Sekar Ramachandran, Jon W. Erickson, Henry H. Le, Zhihan-Emily Wang, Bryant Blank, Kai Su Greene, Richard A. Cerione
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124719311313

Internet

http://www.sciencedirect.com/science/article/pii/S2211124719311313

Similar Items